Soft drugs: building rapid, predictable inactivation into topical therapies
- Review of soft drug design: molecules built to be rapidly and predictably inactivated by metabolism after acting.
- Typically close analogues of a validated lead, with a hydrolytically labile group (often an ester) as the deliberate soft spot.
- Highlights topical soft drugs in development, where local skin activity and low systemic exposure are the goal.
- Also covers practical considerations, open challenges and future directions.
💡 Points
For anyone optimizing a topical lead, the useful message is that the metabolic soft spot is a design input, not a liability to be hunted down late. Tuning ester lability so the compound survives in skin but clears quickly in plasma is a tractable, SAR-friendly problem, and it sidesteps a lot of systemic safety work. The risk is the usual one: inter-species and skin-versus-blood esterase differences can make preclinical clearance misleading.